ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Will Danaher stock hit new highs in 2024?

Danaher stock price outlook

Danaher Corporation (NYSE: DHR) shares went into a tailspin when the Abcam deal came into question, but the dip turned out to be a buying opportunity in this life-sciences company. The dip hit bottom soon after, and even weak guidance could not lower the market. Since then, the stock price has rebounded to reclaim all the lost ground because the fear was unfounded, and now the rebound is gaining momentum. The company updated what was overly cautious guidance, sending the stock to a new multi-year high. The question is if it can move higher from here and when.

Analysts call the bottom in Danaher Corporation

The analysts have yet to issue revisions based on the new guidance. Even so, the trend ahead of the release is favorable to share prices, and the guidance aligns with an outlook for market bottoming. Marketbeat.com tracks 17 analysts with current ratings, and the data has two significant trends. The first is that the consensus sentiment is up from Hold to Moderate Buy compared to last year. 

The 2nd is that the price target trended lower over the last year but hit bottom last month. Since then, the target has begun to edge higher, with analysts at firms like Goldman Sachs expecting a rebound in life sciences this year. 

In Goldman Sachs's view, the life sciences industry is normalizing after the COVID-19 runup and is expected to return to growth in 2025 and 2026. They target 5% growth in both years but may underestimate the market turnaround. The rise of AI is driving a new age of healthcare innovation that will impact it at all levels. Until then, the consensus target assumes about 8% upside for the market, enough to set a two-year high. 

Regarding the consensus for earnings and the update to guidance, the seventeen analysts tracked by Marketbeat.com expect a near-30% decline in revenue with a weakened margin to compound the bottom line shrinkage. That’s double the new guidance expected decline, and why the stock advanced following the news.  

The Danaher dividend cut doesn’t matter 

Danaher pays a dividend and recently cut the distribution, but it doesn’t matter to the long-term trajectory of the stock price. The yield was small before the cut and not much smaller after, about 0.4%, with shares near $235, because the company chose to invest in its turnaround and growth. The cut was worth 11% to investors but frees up cash flow, allowing the company to focus on future revenue, margin expansion and earrings. Ultimately, the company only pays dividends because some investors and mutual funds will only invest in dividend-paying stocks. 

The balance sheet is in fine shape. The company carries debt, but leverage is low, and the cash position is solid despite an acquisition made this year. The company bought Abcam, a leader in protein research tools, for $5.7 billion and closed the deal in December. It should add 2.5% to 3% to the top line, while synergies aid bottom-line results. 

The technical outlook: Danaher advances, faces resistance

The price action in Danaher is solid but may not immediately take the stock to a new high. The market struggles with resistance at a critical pivot point and may fall back to firmer support levels before moving much higher. In this scenario, support is likely at the $220 level, which coincides with the 150-day EMA and a target for robust support. So long as the market shows support at or near this level, it should continue sideways within the upper portion of its trading range with a chance of setting new highs in the year’s first half. If not, the stock could retest support as low as the $200 level and sustain a rally until the 2nd half of the year.  

Danaher stock price chart

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.